 In August, Kite has filed the first CAR-T candidate in Europe, seeking approval of its axicabtagene ciloleucel (KTE-C19) for two types of non-Hodgkin's lymphoma (NHL).In March 2011, Kite Pharma received $15 million in Series A venture cash.In May 2013, Kite Pharma completed a $35 million financing of Series A preferred stock.